JOHNSON & JOHNSON

ISIN: US4781601046 WKN: 478160104 Asset Class: Stock



Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures		Liabilities and equity		Liabilities and equity		iabilities and equity
Current assets	53,495,000,000		55,294,000,000		60,979,000,000	
Common stock capital		3,120,000,000		3,120,000,000		3,120,000,000
Fixed assets	114,063,000,000		132,084,000,000		121,039,000,000	
Equity capital of a company		68,774,000,000		76,804,000,000		74,023,000,000
Cash and cash equivalents	21,859,000,000		14,127,000,000		14,487,000,000	
Accrued liabilities		7,149,000,000		6,767,000,000		8,898,000,000
Other assets	-		-		-	
Current liabilities		46,282,000,000		55,802,000,000		45,226,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		52,502,000,000		54,772,000,000		62,769,000,000
Different income		-		-		-
Other liabilities		15,179,000,000		13,443,000,000		15,399,000,000
Total assets	167,558,000,000	167,558,000,000	187,378,000,000	187,378,000,000	182,018,000,000	182,018,000,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	131,900	152,700	141,700
Equity ratio	41.04%	40.99%	40.67%
Debt-equity ratio	143.64%	143.97%	145.89%

Others

	2023	2022	2021
Tax Expense Rate	11.53%	17.42%	8.33%

JOHNSON & JOHNSON

ISIN: US4781601046 WKN: 478160104 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	85,152,000,000	95,015,000,000	93,758,000,000
Net income	13,326,000,000	17,941,000,000	20,878,000,000
EBIT	14,119,538,400	20,759,887,500	22,079,137,300
Operating income before taxes	15,062,000,000	21,725,000,000	22,776,000,000
Cash Flow	22,791,000,000	21,194,000,000	23,410,000,000
Net interest income	14,000,000	-400,000,000	-755,000,000
Research and development expenses	15,048,000,000	14,752,000,000	14,744,000,000
Income taxes	1,736,000,000	3,784,000,000	1,898,000,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	605,748	583,841	620,841

Board of Directors

Members of Management Board			
Jennifer Doudna	Member of Board of Directors		
Mark McClellan	Member of Board of Directors		
Mary Beckerle	Member of Board of Directors		
Nadja West	Member of Board of Directors		
Paula Johnson	Member of Board of Directors		
Anne Mulcahy	Member of Board of Directors		
D. Davis	Member of Board of Directors		
Darius Adamczyk	Member of Board of Directors		
Eugene Woods	Member of Board of Directors		
Hubert Joly	Member of Board of Directors		
Marillyn Hewson	Member of Board of Directors		
Mark Weinberger	Member of Board of Directors		
Joaquin Duato	Chairman of Managing Board		
James Swanson	Member of Executive Committee		
Jennifer Taubert	Member of Executive Committee		
Joseph J. Wolk	Member of Executive Committee		
Kathy Wengel	Member of Executive Committee		
Liz Forminard	Member of Executive Committee		
Peter M. Fasolo	Member of Executive Committee		
Vanessa Broadhurst	Member of Executive Committee		
William N. Hait	Member of Executive Committee		